What is IDEAYA Biosciences, Inc.'s market cap?

IDEAYA Biosciences, Inc. (IDYA) has a market capitalization of $3.5B and trades on NASDAQ.

What is IDEAYA Biosciences, Inc.'s revenue and profitability?

IDEAYA Biosciences, Inc. generated $232.3M in trailing twelve-month revenue with a net loss of $140.1M, representing a net margin of -3921.1%, with free cash flow of -$87.9M. These figures are based on the Q1 2026 filing.

Who are IDEAYA Biosciences, Inc.'s competitors?

IDEAYA Biosciences, Inc.'s key competitors include Tango Therapeutics, Amgen, Bristol Myers Squibb, and others. These companies compete in similar markets and product categories.

Who does IDEAYA Biosciences, Inc. partner with?

IDEAYA Biosciences, Inc.'s notable partners include Pfizer, Gilead Sciences, Servier, and others.

Where is IDEAYA Biosciences, Inc. headquartered?

IDEAYA Biosciences, Inc. is headquartered in United States of America and employs approximately 124 people. It has been publicly traded since 2019.

IDEAYA Biosciences, Inc.

IDYA

IDEAYA Biosciences is a precision medicine oncology company focused on the discovery and development of targeted therapies for cancer.

Market cap

$3.54B+59.4%

Revenue$232.3M+5,822%

Net income-$140.1M+54.4%

Free cash flow-$87.9M+67.2%

EPS (diluted)-$1.60+56.2%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 5, 2026

Revenue$6.6MBeat by $1.5M EPS-$1.11Miss by $0.04

Read the full report

Next report

Aug 10, 2026 (In 1 week)

Revenue estimate$8.0M

EPS estimate-$1.06

Financials

Q1 2026

Income statement

See full

Revenue$6.6M—

Operating income-$108.5M-28.6%

Net income-$98.5M-36.5%

EPS (diluted)-$1.11-35.4%

Balance sheet

See full

Cash & equivalents$157.5M+21.2%

Total debt$28.6M+10.1%

Total equity$937.3M-8.5%

Total assets$1.0B-6.4%

Cash flow

See full

Operating cash flow-$75.2M-24.6%

CapEx$967.0K-27.3%

Free cash flow-$76.1M-23.5%

Valuation & ratios

Valuation

See full

Market cap$3.54B+59.4%

Enterprise value$3.41B+62.2%

P/S15.2×—

Returns & leverage

See full

Return on equity-14.3%-5.0pp

Debt / equity0×0.0×

Current ratio10.7×-3.2×

Competitors

By market cap

Amgen$203.07B+25.3%

Bristol-Myers Squibb$127.75B+32.1%

Erasca, Inc.$6.6B+1,260%

Tango Therapeutics$4.4B+502%

IDEAYA Biosciences, Inc.$3.5B+61.5%

Aura Biosciences, Inc.$740.6M+70.9%

OnKure Therapeutics, Inc.$163.6M+68.7%

Aprea Therapeutics, Inc.$7.7M-25.7%

By revenue growth

IDEAYA Biosciences, Inc.+5,822%

Tango Therapeutics+39.0%

Amgen+9.1%

Bristol-Myers Squibb+1.8%

By net margin

Amgen20.96%+3.6pp

Bristol-Myers Squibb15.01%+3.8pp

Tango Therapeutics-188.15%+135pp

IDEAYA Biosciences, Inc.-3,921.1%+7,769pp

Profile

IDEAYA Biosciences is a precision medicine oncology company focused on the discovery and development of targeted therapies for cancer. The company leverages a synthetic lethality platform and antibody-drug conjugate expertise to create treatments tailored to specific genetic drivers of solid tumors. Its core value proposition lies in identifying translational biomarkers to deliver first-in-class therapies that improve clinical outcomes for molecularly defined patient populations.

Competitive position

A leading precision medicine firm in the synthetic lethality space with multiple first-in-class candidates in clinical trials.

GeographiesUnited States, China, Europe

Customer segmentsOncology patients, Global pharmaceutical firms

Business modelR&D intensive, Licensing and Royalties, B2B Partnerships

SuppliersContract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic research institutions, Specialized chemical and API suppliers

CustomersPharmaceutical licensing partners, Specialty oncology clinics, Hospitals, Diagnostic laboratories

CountryUnited States of America

Listed2019

Employees124.0

CEOYujiro S. Hata

SectorHealthcare

IndustryBiotechnology

Websiteideayabio.com

FilingsSEC EDGAR

Ask your AI about IDEAYA Biosciences, Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is IDEAYA Biosciences, Inc.'s market cap?: IDEAYA Biosciences, Inc. (IDYA) has a market capitalization of $3.5B and trades on NASDAQ.
What is IDEAYA Biosciences, Inc.'s revenue and profitability?: IDEAYA Biosciences, Inc. generated $232.3M in trailing twelve-month revenue with a net loss of $140.1M, representing a net margin of -3921.1%, with free cash flow of -$87.9M. These figures are based on the Q1 2026 filing.
Who are IDEAYA Biosciences, Inc.'s competitors?: IDEAYA Biosciences, Inc.'s key competitors include Tango Therapeutics, Amgen, Bristol Myers Squibb, and others. These companies compete in similar markets and product categories.
Who does IDEAYA Biosciences, Inc. partner with?: IDEAYA Biosciences, Inc.'s notable partners include Pfizer, Gilead Sciences, Servier, and others.
Where is IDEAYA Biosciences, Inc. headquartered?: IDEAYA Biosciences, Inc. is headquartered in United States of America and employs approximately 124 people. It has been publicly traded since 2019.